OPTN and cancer: Complementing this, emerging therapeutic modalities, such as Proteolysis-Targeting Chimeras (PROTACs), RNA-based therapeutics, and Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing, may offer innovative avenues to precisely manipulate OPTN expression or stability in cancer cells [43].